Kyu Tae Kim

USPTO Granted Patents = 15 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 291(Granted Patents)

Location History:

Gyeonggi-do, KR (2019 - 2023)
Seoul, KR (2003 - 2024)
Yongin-si, KR (2024)

Company Filing History:

Hynix Semiconductor Inc.

Years Active: 2003-2025

Loading Chart...

15 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12410261 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2025-09-09),

2. 12116417 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2024-10-15),

3. 12090171 - Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof (2024-09-17),

4. 12026323 - Optical digital pen by use of light scattering (2024-07-02),

5. 11970547 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2024-04-30),

6. 11708409 - Antibody or antigen-binding fragment thereof that specifically recognizes B cell malignancies, chimeric antigen receptor comprising same, and uses thereof (2023-07-25),

7. 11649294 - Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same (2023-05-16),

8. 11534462 - Antibody or antigen binding fragment thereof for specifically recognizing B cell malignancy, chimeric antigen receptor comprising same and use thereof (2022-12-27),

9. 11248059 - Antibody having improved stability and specifically binding to HER2 (2022-02-15),

10. 10465008 - Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease (2019-11-05),

11. 8823091 - Semiconductor device having saddle fin transistor and manufacturing method of the same (2014-09-02),

12. 8350321 - Semiconductor device having saddle fin transistor and manufacturing method of the same (2013-01-08),

13. 8164156 - Fuse structure for high integrated semiconductor device (2012-04-24),

14. 6803260 - Method of horizontally growing carbon nanotubes and field effect transistor using the carbon nanotubes grown by the method (2004-10-12),

15. 6515339 - Method of horizontally growing carbon nanotubes and field effect transistor using the carbon nanotubes grown by the method (2003-02-04),

Title: **Innovations of Kyu Tae Kim: Pioneering Anti-Cancer Antibodies**

Introduction

Kyu Tae Kim, based in Gyeonggi-do, South Korea, is a prominent inventor known for his significant contributions in the field of medical science, particularly in developing antibodies for cancer treatment. With a portfolio that includes eight patents, he has uniquely positioned himself as a leading innovator in combating various types of cancer.

Latest Patents

Among his latest patents, Kyu Tae Kim has developed a novel anti-HER2 antibody or an antigen-binding fragment thereof, which is crucial for the prevention and treatment of cancers such as breast and gastric cancer. This remarkable antibody specifically binds to HER2, distinguishing itself by targeting a different epitope than the well-known trastuzumab. His research indicates that this antibody demonstrates enhanced efficacy against HER2-unexpressed cancer cells, which are unresponsive to trastuzumab, providing a promising avenue for treatment. Furthermore, when administered in combination with trastuzumab, it remarkably enhances the killing ability against targeted cancer cells.

Additionally, Kyu Tae Kim has introduced an antibody specifically designed to target B cell malignancies, again in the form of a chimeric antigen receptor (CAR). This innovative approach, which leverages the distinct binding properties of a new CD19-targeting antibody, aims to induce effective immune responses against blood cancers. His work in this area sets the stage for advanced therapies that harness the body's immune system to combat cancer more effectively.

Career Highlights

Kyu Tae Kim has made significant strides in his career through his associations with prominent companies in the biotechnology sector. Notably, he has worked with Abclon Inc., where he contributed to cutting-edge research in immunotherapy, and GC Cell Corporation, focusing on innovative cell therapies for cancer treatment.

Collaborations

Throughout his journey, Kyu Tae Kim has collaborated with notable professionals in the field, including Jong Seo Lee and Bong Kook Ko. These partnerships have fostered a dynamic environment for innovation, enabling the exchange of ideas and bolstering advancements in cancer research and therapy.

Conclusion

In conclusion, Kyu Tae Kim stands out as a leading inventor whose groundbreaking research and patents are paving the way for new treatments in cancer therapy. His dedication to developing effective antibodies fundamentally shifts how we approach cancer treatment, showing promise not only in potential cures but also in improving the lives of many patients worldwide.

This text is generated by artificial intelligence and may not be accurate.